Albany, NY 10/15/2018 Advanced drug delivery devices include drug-eluting devices that can be further categorized into biodegradable and non-biodegradable drug delivery systems. Biodegradable drug-eluting devices are used for drug delivery and after implantation these devices decompose over time. They are generally made up of biocompatible...
Avadel Pharmaceuticals plc, a company focused on providing innovative medicines for chronic urological, central nervous system, and sleep disorders, presented data from two abstracts from Phase 3 clinical trials of NOCTIVA? at the American Urogynecologic Society Annual Scientific Meeting, Pelvic Floor Disorder Week 2018 in Chicago, Illinois fro
Dar Bioscience, Inc., a clinical-stage, women s health-focused biopharmaceutical company, today announced it will be presenting scientific and technical details on its innovative intra-vaginal ring technologies at the Partnership Opportunities in Drug Delivery meeting being held on the 17th and 18th of October in Boston, Massachusetts.
HYDERABAD: Dr Reddys Laboratories Ltd Monday announced it has received the approval of the US Food and Drug Administration to market aspirin and dipyridamole capsules in the USA. Aggrenox is a registered trademark of pharmaceutical major Boehringer Ingelheim, the release said. The Aggrenox brand and the generic drug registered sales of approximatel
HYDERABAD, India& PRINCETON, N.J. Dr. Reddy s Laboratories Ltd today announced receipt of approval for Aspirin and Extended-Release Dipyridamole Capsules, a therapeutic equivalent generic version of Aggrenox Capsules in the United States market from the U.S. Food and Drug Administration. The Aggrenox brand and generic had U.S. sales of appro
NEW DELHI- Dr. Reddy's Laboratories Ltd. announced Monday the receipt of approval for Aspirin and Extended-Release Dipyridamole Capsules, a therapeutic equivalent generic version of Aggrenox Capsules in the United States market from the U.S. Food and Drug Administration. The company said it is working towards launching the product. Aggrenox brand,
EyePoint Pharmaceuticals, Inc., a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, announced today that the U. S. Food and Drug Administration has approved YUTIQ? for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The approval of YUTIQ
Pulmonary Drug Delivery Devices/Systems Market includes devices for delivering drugs through medical devices such as inhalers and nebulizers in patients with respiratory illnesses such as asthma. The devices are based on diverse delivery mechanisms, ...
U.S. is the prominent market in the region. Europe market is expected to expand at a CAGR of 6.6% during the forecast period i.e. 2017-2024. Further, U.K.& Germany are the major contributor to the growth of transdermal drug delivery market. In addition to this, U.K. transdermal drug delivery market is expected to reach USD 249.1 Million by the end
EVENT: Health and Human Services Department; Food and Drug Administration holds a joint meeting of the Psychopharmacologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee to discuss the efficacy, safety, and risk-benefit profile of new drug application 210417 for buprenorphine and samidorphan sublingual tablets,.
EVENT: Health and Human Services Department; Food and Drug Administration holds a joint meeting of the Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee to discuss new drug application 209774, for an immediate-release oral tablet formulation of oxycodone. The drug is intended to res
ITF Pharma, a U.S.- based specialty pharmaceutical company and a subsidiary of Italfarmaco, a privately-held European specialty pharmaceutical company, announced today the U.S. availability of its first commercial product, TIGLUTIK? oral suspension, for the treatment of amyotrophic lateral sclerosis. ITF Pharma has begun offering TIGLUTIK in th
BioPharmX Corporation, a specialty pharmaceutical company developing products for the dermatology market, today announced that it has enrolled the first subject in a Phase 2 b clinical trial of BPX-04, a novel topical gel formulation of minocycline for the treatment of rosacea. The 12- week, multi-center study will evaluate BPX-04, a 1% topical min
ICU Medical has teamed up with IT security company Imprivata to protect network-connected infusion pumps from cyber attacks. In response to these threats, ICU has enlisted the support of healthcare security specialist Imprivata. "Infusion pumps are rapidly increasing in their level of integration on hospital networks as EHR integration is becoming
Transparency Market Research has published a new report titled Gene Delivery System Market Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2017 2025. Key players introduce advanced technologies for drug delivery systems in North America and Europe; therefore, these regions are likely to account for a dominant share
Visiongain, a independent media company, issued the following news:. Visiongain's new report Pharmaceutical Packaging Market Report 2018-2028: Global Forecasts by Material, by Product and by Delivery System Plus Profiles of Leading Companies and Leading National Market Analysis indicates that the pharmaceutical packaging market will see over $94 bn
Albany, NY 10/12/2018 Rapid infuser is a procedure/treatment which involves administration of rapid fluid used during surgical procedure. Rapid infuser device is able to deliver the fluid from slow to rapid continuous flow. Rapid infuser device is prominently used in emergency situations for safe and effective treatment.
By a News Reporter-Staff News Editor at Cancer Vaccine Week Staff editors report on the newly launched clinical trial, NCT03693612, which has the following summary description: "The purpose of this study is to evaluate if the combination of GSK3359609 and tremelimumab is safe and tolerable and provides significant survival benefit to subjects wit
By a News Reporter-Staff News Editor at Biotech Week Staff editors report on the newly launched clinical trial, NCT03691077, which has the following summary description: "Ocrelizumab is a humanized anti-CD20 monoclonal antibody that showed in phase III trials a powerful effect on relapse rate and lesion load accumulation in the relapsing form of
BioPharmX Corporation, a specialty pharmaceutical company developing products for the dermatology market, today announced that it has enrolled the first subject in a Phase 2 b clinical trial of BPX-04, a novel topical gel formulation of minocycline for the treatment of rosacea. "Dermatologists and their patients are still searching for effective
By a News Reporter-Staff News Editor at Clinical Trials Week Staff editors report on the newly launched clinical trial, NCT03691324, which has the following summary description: "Inhalation drugs are essential in the treatment of COPD, in controlling symptoms and preventing exacerbations. The aim of this pilot study is to collect data necessary f
-CURE Pharmaceutical, an innovative drug delivery and development company, will be presenting at this year`s CannX Conference on October 15 at 11:15 AM in Tel Aviv, Israel. CURE Pharmaceutical CEO Rob Davidson will present on Maximizing and Understanding the Benefits of Proprietary Delivery Technologies for Increasing Bioavailability of Cannabinoid
According to news reporting from George Town, Malaysia, by NewsRx journalists, research stated, "Magnetic nanocellulose alginate hydrogel beads are produced from the assembly of alginate and magnetic nanocellulose as a potential drug delivery system. For more information on this research see: Magnetic nanocellulose alginate hydrogel beads as potent